Cytotoxicity and Potential Antiviral Evaluation of Violacein Produced by Chromobacterium violaceum

Memorias do Instituto Oswaldo Cruz

Volumn 98, Issue 6, 2003, Pages 843-848

  Andrighetti Frohner C R ^a   Antonio, R V ^a   Creczynski Pasa, T B ^a,b   Barardi, C R M ^b   Simoes C M O ^a  

^a Lab de Virologia Aplicada   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Adenovirus; Antiviral; Cytotoxicity; Hepatitis A virus; Herpes simplex virus type 1; MTT assay; Poliovirus; Rotavirus; Violacein

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACICLOVIR; ANTIVIRUS AGENT; TRYPAN BLUE; UNCLASSIFIED DRUG; VIOLACEIN;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL DESTRUCTION; CELL STRUCTURE; CELL VIABILITY; CHROMOBACTERIUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; HEP 2 CELL; HEPATITIS A VIRUS; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MICROSCOPY; MONOLAYER CULTURE; NONHUMAN; POLIOMYELITIS VIRUS; ROTAVIRUS; STATISTICAL SIGNIFICANCE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALIA; CHROMOBACTERIUM; CHROMOBACTERIUM VIOLACEUM; HEPATITIS A VIRUS; HUMAN ADENOVIRUS TYPE 5; HUMAN HERPESVIRUS 1; HUMAN POLIOVIRUS 2; POLIOVIRUS; ROTAVIRUS; SIMIAE; SIMIAN ROTAVIRUS; SIMPLEXVIRUS; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 0346991927     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762003000600023     Document Type: Article

References (42)

1. Balfour HH 1999. Drug therapy: antiviral drugs. N Engl J Med 340: 1255-1268.
2. Barardi CRM, Emslie KR, Vesey G, Williams KL 1998. Development of a rapid and sensitive quantitative assay for rotavirus based on flow cytometry. J Virol Meth 74: 31-37.
3. Bedard J, May S, Barbeau D, Yuen L, Rando RF, Bowlin TL: 1999. A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors. Antiviral Res 41: 35-43.
4. Bedoya LM, Palomino-Sanchez S, Abad MJ, Bermejo P, Alcami J 2001. Anti-HIV activity of medicinal plant extracts. J Ethnopharmacol 77: 113-116.
5. Betancur-Galvis L, Morales GE, Forero JE, Roldan J 2002. Cytotoxic and antiviral activities of Colombian medicinal plant extracts of the Euphorbia genus. Mem Inst Oswaldo Cruz 97: 541-546.
6. Bromberg N, Duran N 2001. Violacein transformation by peroxidases and oxidases: implications on its biological properties. J Mol Catal B: Enzim 11: 463-467.
7. Burleson FG, Chamberts TM, Wiedbrauk DL 1992. Virology. A Laboratory Manual, Academic, San Diego, 250 pp.
8. Carmichael J, Degraff WG, Gazdar AF, Minna JD, Mitchell JB 1987. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942.
9. De Logu A, Loy G, Pellerano ML, Bonsignore L, Schivo ML 2000. Inactivation of HSV-1 and HSV-2 and prevention of cell-to-cell virus spread by Santolina insularies essential oil. Antiviral Res 48: 177-185.
10. Denizot F, Lang R 1986. Rapid colorimetric assay for cell growth and survival. J Immunol Meth 89: 271-277.
11. Duran N 1998. Formulation of cyclodextrin/violacein based medicine - comprises enhancement of violacein solubility, with increase in versatility. BR PI 9801307-A, 4 Mar.
12. Duran N, Menck CFM 2001. Chromobacterium violaceum: a review of pharmacological and industrial perspective. Crit Rev Microbiol 27: 201-222.
13. Duran N, Antonio RV, Haun M, Pilli RA 1994. Biosynthesis of a trypanocide of Chromobacterium violaceum. World J Microbiol Biotechnol 10: 686-691.
14. Eisenbrand G, Pool-Zobel B, Baker V, Balls M, Blaauboer BJ, Boobis A, Carere A, Kevekordes S, Lhuguenot JC, Pieters R, Kleiner J 2002. Methods of in vitro toxicology. Food Chem Toxicol 40: 193-236.
15. Estes MK, Graham DY, Mason BB 1981. Proteolytic enhancement of rotavirus infectivity molecular mechanism. J Virol 39: 879-888.
16. Glatthaar-Saalmüller B, Sacher F, Esperester A 2001. Antiviral activity of an extract derived from roots of Eleutherococcus senticosus. Antiviral Res 50: 223-228.
17. Gulati M, Grover M, Singh S, Singh M 1998. Lipophilic drug derivatives in liposomes. Int J Pharm 165: 129-168.
18. Kaneko H, Keiichiro K, Mori S, Shigeta S 2001. Antiviral activity of NMSO3 against adenovirus in vitro. Antiviral Res 52: 281-288.
19. Law SL, Huang KJ, Chiang CH 2000. Acyclovir-containing liposomes for potencial ocular delivery corneal penetration and absorption. J Control Release 63: 135-140.
20. Leon LL, Miranda CC, De Souza AO, Duran N 2001. Anti-leishmanial activity of the violacein extracted from Chromobacterium violaceum. Antimicrob Agents Chemoth 48: 449-450.
21. Li K, Ma SC, Yang YT, Ye SM, But PP 2002. Antiviral activities of flavonoids and organic acid from Trollius chinesis Bunge. J Ethnopharmacol 79: 365-368.
22. Lotfi K, Zackrisson A, Peterson C 2002. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis and resistance. Cancer Lett 178: 141-149.
23. May G, Brummer B, Ott H 1991. Treatment of prophylaxis of polio and herpes virus infections - comprises admin, of 3-(1,2-dihydro-5-(5-hydroxy-1H- indol-3-yl)-2-oxo-3H-pyrrole-3-ylidene)-1,3-dihydro-2H-indol-2-one. Ger Offen DE 3935066, 25 April.
24. Melo PS, Maria SS, Vidal BC, Haun M, Duran N 2000. Violacein cytotoxicity and induction of apoptosis in V79 cells. In vitro Cell Dev Biol Anim 36: 639-543.
25. Mossmann T 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55-63.
26. Nielsen J 2002. Combinatorial synthesis of natural products. Curr Opin Chem Biol 6: 297-305.
27. Pillay D, Zambon M 1998. Antiviral drug resistance. Brit Med J 317: 660-662.
28. Pujol CA, Errea MI, Matulewicz MC, Damonte EB 1996. Antiherpetic activity of S1, an algal derived sulphated galactan. Phytoth Res 10: 410-413.
29. Reed LJ, Muench H 1938. A simple method of estimating fifty per cent endpoints. Am J Hyg 27: 493-497.
30. Semple SJ, Pyke SM, Reynolds G, Flower RLP 2001. In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus. Antiviral Res 49: 169-178.
31. 50 -values and cell survival. Eur J Clin Chem Clin Biochem 33: 813-823.
32. Simões CMO, Amoros M, Girre L 1999. Mechanism of antiviral activity of triterpenoid saponins. Phytoth Res 21: 317-325.
33. Smee DF, Morrison AC, Barnard DL, Sidwell RW 2002. Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J Virol Meth 106: 71-79.
34. Takahashi K, Matsuda M, Ohashi K, Taniguchi K, Nakagomi O, Abe Y, Mori S, Sato N, Okutani K, Shigeta S 2001. Analysis of anti-rotavirus activity of extract from Stevia rebaudiana. Antiviral Res 49: 15-24.
35. Takeuchi H, Baba M, Shigeta S 1991. An application of tetrazolium (MTT) colorimetric assay for the screening of anti-herpes simplex virus compounds. J Virol Meth 33: 61-71.
36. Todryk S, Melcher A, Bottley G, Gough M, Vile R 2001. Cell death associated with genetic prodrug activation therapy of colorectal cancer. Cancer Lett 174: 25-33.
37. Vlietinck AJ, De Bruyne T, Vanden Berghe DA 1997. Plant substances as antiviral agents. Curr Org Chem 1: 307-344.
38. Vlietinck AJ, De Bruyne T, Pieters LA 1998. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med 64: 97-109.
39. Vlietinck AJ, Vanden Berghe DA 1998. Leads for antivirals from tradicional medicines. In HDV Prebdergastm, NL Etkin, DR Harris, PJ Houghton (eds), Plants for Food and Medicine, Royal Botanic Gardens, London, p. 333-344.
40. Walum E, Strenberg K, Jenssen D 1990. Understanding Cell Toxicology: Principles and Pratice, Ellis Howood, New York, p. 97-111.
41. Wilson AP 2000. Cytotoxicity and viability assays. In JRW Masters, Animal Cell Culture, 3rd ed., Oxford University, Oxford, p. 175-219.
42. Wutzler P, Sauerbrei A, Klöcking R, Brögmann B, Reimer K 2002. Virucidal activity and cytotoxicity of the liposomal formulation of povidone-iodine. Antiviral Res 54: 89-97.